

KRIT1 Antibody (monoclonal) (M01)

Mouse monoclonal antibody raised against a partial recombinant KRIT1.

Catalog # AT2652a

Product Information

Application	E
Primary Accession	O00522
Other Accession	NM_004912
Reactivity	Human
Host	mouse
Clonality	monoclonal
Isotype	IgG2a lambda
Clone Names	2C7
Calculated MW	84348

Additional Information

Gene ID	889
Other Names	Krev interaction trapped protein 1, Krev interaction trapped 1, Cerebral cavernous malformations 1 protein, KRIT1, CCM1
Target/Specificity	KRIT1 (NP_004903, 637 a.a. ~ 736 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Dilution	E~~N/A
Format	Clear, colorless solution in phosphate buffered saline, pH 7.2 .
Storage	Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
Precautions	KRIT1 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.


Background

This gene encodes a protein containing four ankyrin repeats, a band 4.1/ezrin/radixin/moesin (FERM) domain, and multiple NPXY sequences. The encoded protein is localized in the nucleus and cytoplasm. It binds to integrin cytoplasmic domain-associated protein-1 alpha (ICAP1alpha), and plays a critical role in beta1-integrin-mediated cell proliferation. It associates with junction proteins and RAS-related protein 1A (Rap1A), which requires the encoded protein for maintaining the integrity of endothelial junctions. It is also a microtubule-associated protein and may play a role in microtubule targeting. Mutations in this gene result in cerebral cavernous malformations. Multiple alternatively spliced transcript variants have been found for this gene.

References

Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Rose JE, et al. Mol Med, 2010 Jul-Aug. PMID 20379614. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. Stockton RA, et al. J Exp Med, 2010 Apr 12. PMID 20308363. Novel KRIT1/CCM1 mutation in a patient with retinal cavernous hemangioma and cerebral cavernous malformation. Reddy S, et al. Graefes Arch Clin Exp Ophthalmol, 2010 Sep. PMID 20306072. Familial versus sporadic cavernous malformations: differences in developmental venous anomaly association and lesion phenotype. Petersen TA, et al. AJNR Am J Neuroradiol, 2010 Feb. PMID 19833796. C329X in KRIT1 is a founder mutation among CCM patients in Sardinia. Cau M, et al. Eur J Med Genet, 2009 Sep-Oct. PMID 19454328.

Images



Detection limit for recombinant GST tagged KRIT1 is approximately 0.03ng/ml as a capture antibody.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.